Literature DB >> 27280509

Prognostic Impact of Postoperative Morbidity After Esophagectomy for Esophageal Cancer: Exploratory Analysis of JCOG9907.

Kozo Kataoka1, Hiroya Takeuchi, Junki Mizusawa, Hiroyasu Igaki, Soji Ozawa, Tetsuya Abe, Kenichi Nakamura, Ken Kato, Nobutoshi Ando, Yuko Kitagawa.   

Abstract

OBJECTIVE: To investigate the influence of infectious complications on the outcome of current standard preoperative chemotherapy followed by surgery for clinical stage II/III esophageal cancer.
BACKGROUND: The impact of postoperative infectious complications on survival after transthoracic esophagectomy remains controversial.
METHODS: Data from a randomized controlled trial (JCOG9907) were used. Infectious complications were classified into three groups: pneumonia, anastomotic leakage, and others. Univariate and multivariate analyses using the Cox proportional hazard model were performed.
RESULTS: Among the 152 analyzed patients, the incidence of pneumonia, leakage, and overall infectious complication were 22 (14%), 21 (14%), and 54 (36%). Overall survival (OS) of patients with any infectious complication was shorter than that of patients without infectious complication [hazard ratio, HR 1.66, 95% confidence interval, CI, (1.02-2.71)] and progression-free survival (PFS) also tended to be shorter in patients with any infectious complication [HR 1.44, (0.92-2.24)]. The OS of patients with pneumonia was shorter than that of patients without pneumonia [HR 1.82, (1.01-3.29)], and PFS also tended to be shorter in patients with pneumonia [HR 1.50, (0.85-2.62)]. The OS of patients with anastomotic leakage (n = 21) was nearly identical to that for patients without leakage [HR 1.06, (0.52-2.13)] and PFS showed the same tendency [HR 1.28, (0.71-2.32)]. Multivariate analysis revealed that pneumonia tended to compromise OS and PFS [HR 1.66, (0.87-3.17) and HR 1.37, (0.75-2.51)].
CONCLUSIONS: These results indicate that postoperative infectious complications may worsen patient prognosis after esophagectomy. Performing esophagectomy without postoperative complications, especially pneumonia, may be beneficial for improving survival outcomes.

Entities:  

Mesh:

Year:  2017        PMID: 27280509     DOI: 10.1097/SLA.0000000000001828

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  57 in total

1.  Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer.

Authors:  Kei Hosoda; Hideki Ushiku; Chikatoshi Katada; Kenji Ishido; Masahiro Niihara; Mikiko Sakuraya; Ippeita Araki; Marie Washio; Hiroki Harada; Keishi Yamashita; Naoki Hiki
Journal:  Langenbecks Arch Surg       Date:  2021-03-20       Impact factor: 3.445

2.  Identification of NCCRP1 as an epigenetically regulated tumor suppressor and biomarker for malignant phenotypes of squamous cell carcinoma of the esophagus.

Authors:  Takashi Miwa; Mitsuro Kanda; Masahiko Koike; Naoki Iwata; Haruyoshi Tanaka; Shinichi Umeda; Chie Tanaka; Daisuke Kobayashi; Masamichi Hayashi; Suguru Yamada; Tsutomu Fujii; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2017-08-14       Impact factor: 2.967

3.  Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy?

Authors:  Masato Hayashi; Takaki Yoshikawa; Masahiro Yura; Sho Otsuki; Yukinori Yamagata; Shinji Morita; Hitoshi Katai; Toshirou Nishida
Journal:  Gastric Cancer       Date:  2019-04-03       Impact factor: 7.370

4.  Results of neoadjuvant therapy followed by esophagectomy for patients with locally advanced thoracic esophageal squamous cell carcinoma.

Authors:  Dong Lin; Longfei Ma; Ting Ye; Yunjian Pan; Longlong Shao; Zuodong Song; Shujun Jiang; Haiquan Chen; Jiaqing Xiang
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

5.  Preoperative controlling nutritional status (CONUT) is useful to estimate the prognosis after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Kazuto Harada; Yoshifumi Baba; Keisuke Kosumi; Masaaki Iwatsuki; Koichi Kinoshita; Kenichi Nakamura; Yasuo Sakamoto; Yuji Miyamoto; Ryuichi Karashima; Kosuke Mima; Hiroshi Sawayama; Mayuko Ohuchi; Akira Chikamoto; Yu Imamura; Masayuki Watanabe; Hideo Baba
Journal:  Langenbecks Arch Surg       Date:  2017-01-30       Impact factor: 3.445

6.  Prolonged antibiotic prophylaxis after thoracoabdominal esophagectomy does not reduce the risk of pneumonia in the first 30 days: a retrospective before-and-after analysis.

Authors:  Marcel Hochreiter; Maria Uhling; Leila Sisic; Thomas Bruckner; Alexandra Heininger; Andreas Hohn; Katja Ott; Thomas Schmidt; Marc Moritz Berger; Daniel Christoph Richter; Markus Büchler; Markus Alexander Weigand; Cornelius Johannes Busch
Journal:  Infection       Date:  2018-06-05       Impact factor: 3.553

7.  Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma.

Authors:  Takanori Kurogochi; Michitaka Honda; Kotaro Yamashita; Masaru Hayami; Akihiko Okamura; Yu Imamura; Shinji Mine; Masayuki Watanabe
Journal:  Surg Today       Date:  2018-10-01       Impact factor: 2.549

8.  The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Masashi Takeuchi; Hirofumi Kawakubo; Shuhei Mayanagi; Kayo Yoshida; Tomoyuki Irino; Kazumasa Fukuda; Rieko Nakamura; Norihito Wada; Hiroya Takeuchi; Yuko Kitagawa
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

9.  Impact of pretreatment asymptomatic renal dysfunction on clinical course after esophagectomy.

Authors:  Yuki Kirihataya; Kohei Wakatsuki; Sohei Matsumoto; Hiroshi Nakade; Tomohiro Kunishige; Shintaro Miyao; Masayuki Sho
Journal:  Surg Today       Date:  2020-08-29       Impact factor: 2.549

Review 10.  The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms.

Authors:  Kosuke Mima; Shuji Ogino; Shigeki Nakagawa; Hiroshi Sawayama; Koichi Kinoshita; Ryuichi Krashima; Takatsugu Ishimoto; Katsunori Imai; Masaaki Iwatsuki; Daisuke Hashimoto; Yoshifumi Baba; Yasuo Sakamoto; Yo-Ichi Yamashita; Naoya Yoshida; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  Surg Oncol       Date:  2017-07-21       Impact factor: 3.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.